Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2019 Earnings Conference Call - Final Transcript
May 06, 2019 • 04:30 pm ET
Good afternoon, ladies and gentlemen, and welcome to the Syndax's First Quarter 2019 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we'll conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions)
I would now like to turn the call over to your host, Ms. Melissa Forst with Argot Partners. Please go ahead.
Thank you, operator. Welcome and thank you to those of you joining us today for Syndax's first quarter 2019 financial results conference call. Joining us this afternoon for prepared remarks will be Dr. Briggs Morrison, Chief Executive Officer; Michael Metzger, President and Chief Operating Officer; and Rick Shea, Chief Financial Officer. And also joining us on today's call for the question-and-answer session will be Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer.
This call is being accompanied by a slide deck that has been posted on the company's website, so I would ask you to please turn to the forward-looking statements on slide two.
Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10-Q as well as other reports filed with the SEC. Any forward-looking statements represent the company's views as of today, May 6, 2019, only. A replay of this call will be available on the company's website, www.syndax.com following the call.
And with that, I'm pleased to turn the call over you, Dr. Briggs Morrison, Chief Executive Officer of Syndax.
Briggs W. Morrison
Thank you very much, Melissa. And thank you to everyone for joining us on today's call and on the webcast. Slide three provides a high level summary of our current corporate priorities. As we progress through this year, we continue to focus our resources on two incredibly exciting opportunities. The first is, we are anticipating a positive read out of E2112, our Phase III trial of entinostat in hormone receptor positive breast cancer and the subsequent filing of our first NDA and the corresponding launch of our first product.
I want to again emphasize that a positive overall survival trial in hormone receptor positive HER2- breast cancer would be a landmark result and would be transformative for Syndax, its shareholders, then most importantly for patients. We believe the entinostat opportunity in hormone receptor positive breast cancer carries blockbuster potential. The E2112 Data Safety Monitoring Committee recently completed their scheduled second quarter interim analysis and has informed us that the trial will continue as planned. This result is encouraging and consistent with our base case assumption.
We will now turn our attention to the upcoming fourth quarter '19 analysis. I'd also like to take a moment to congratulate Dr. Roisin